Annotation Detail for INPP4A

Basic Information
Top
Pathway ID | Pathway Name |
---|
PWY-6368 | 3-phosphoinositide degradation |
Pathway ID | Pathway Name |
---|
hsa00562 | Inositol phosphate metabolism |
hsa01100 | Metabolic pathways |
hsa04070 | Phosphatidylinositol signaling system |
Desease ID | Desease Name |
---|
2074 | Asthma |
Chemical ID |
Chemical Name |
Interaction |
Interaction Action |
Publication |
---|
C023514 |
2,6-dinitrotoluene |
2,6-dinitrotoluene affects the expression of INPP4A mRNA | affects expression | 21346803
|
D000643 |
Ammonium Chloride |
Ammonium Chloride affects the expression of INPP4A mRNA | affects expression | 16483693
|
D016572 |
Cyclosporine |
Cyclosporine results in increased expression of INPP4A mRNA | increases expression | 20106945
|
Disease ID |
Disease Name |
Direct Evidence |
Inference Chemical Name |
Inference Score |
Publication |
---|
MESH:D000138 |
Acidosis |
|
Ammonium Chloride |
4.30 | 18287403 |
MESH:D006528 |
Carcinoma, Hepatocellular |
|
2,6-dinitrotoluene |
1.79 | 16705839 |
MESH:D002471 |
Cell Transformation, Neoplastic |
|
2,6-dinitrotoluene |
7.56 | 6135515 |
MESH:D002471 |
Cell Transformation, Neoplastic |
|
Cyclosporine |
7.56 | 12371664 |
MESH:D002779 |
Cholestasis |
|
Cyclosporine |
3.24 | 19486331 |
MESH:D003490 |
Cyanosis |
|
2,6-dinitrotoluene |
4.67 | 18551238 |
MESH:D056486 |
Drug-Induced Liver Injury |
|
2,6-dinitrotoluene |
2.06 | 18551238 21346803 |
MESH:D005234 |
Fatty Liver |
|
Cyclosporine |
3.34 | 19224547 |
MESH:D005355 |
Fibrosis |
|
Cyclosporine |
3.79 | 12639820 12168785 |
MESH:D005885 |
Gingival Hyperplasia |
|
Cyclosporine |
4.96 | 8708960 |
MESH:D006457 |
Hemoglobinuria, Paroxysmal |
|
Cyclosporine |
5.16 | 15720958 |
MESH:D006973 |
Hypertension |
|
Cyclosporine |
2.23 | 10903974 |
MESH:D007638 |
Keratoconjunctivitis Sicca |
|
Cyclosporine |
5.31 | 15604871 |
MESH:D007674 |
Kidney Diseases |
|
Cyclosporine |
2.56 | 18776723 10903974 8314463 |
MESH:D007680 |
Kidney Neoplasms |
|
2,6-dinitrotoluene |
8.59 | 16705839 |
MESH:D007680 |
Kidney Neoplasms |
|
Cyclosporine |
8.59 | 12371664 |
MESH:D008113 |
Liver Neoplasms |
|
2,6-dinitrotoluene |
2.28 | 7678174 |
MESH:D008114 |
Liver Neoplasms, Experimental |
|
2,6-dinitrotoluene |
2.79 | 2876784 2876786 6135515 |
MESH:D008664 |
Metal Metabolism, Inborn Errors |
|
Cyclosporine |
5.65 | 16801185 |
MESH:D009336 |
Necrosis |
|
2,6-dinitrotoluene |
4.60 | 18551238 7678174 |
MESH:D009402 |
Nephrosis, Lipoid |
|
Cyclosporine |
5.31 | 17954296 |
MESH:D009404 |
Nephrotic Syndrome |
|
Cyclosporine |
3.70 | 19348381 18481113 |
MESH:D009784 |
Occupational Diseases |
|
2,6-dinitrotoluene |
3.88 | 16049721 |
MESH:D011230 |
Precancerous Conditions |
|
Cyclosporine |
3.64 | 12371664 |
MESH:D011565 |
Psoriasis |
|
Cyclosporine |
2.34 | 16882103 |
MESH:D012640 |
Seizures |
|
2,6-dinitrotoluene |
2.82 | 18551238 |
MESH:D001749 |
Urinary Bladder Neoplasms |
|
2,6-dinitrotoluene |
2.42 | 16049721 |
MESH:D014571 |
Urologic Neoplasms |
|
2,6-dinitrotoluene |
5.06 | 10091137 |
MESH:D014605 |
Uveitis |
|
Cyclosporine |
4.85 | 1336536 |
MESH:D014985 |
Xerophthalmia |
|
Cyclosporine |
5.31 | 17120751 |